Theriva Biologics
TOVX
74 hedge funds and large institutions have $27.4M invested in Theriva Biologics in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 7 closing their positions.
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
6% more funds holding
Funds holding: 70 → 74 (+4)
0% less ownership
Funds ownership: 0% → 0% (-0%)
19% less capital invested
Capital invested by funds: $34M → $27.4M (-$6.56M)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.45M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.09M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$90.7K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$62.8K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$55.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$1.55M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.29M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$356K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$342K |
| 5 |
Millennium Management
New York
|
-$307K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OCM
76
Oakview Capital Management
Dallas,
Texas
| $2K | – | – | – |
|
77
Citigroup
New York
| $1K | -$76.7K | -11 | Closed |
|
|
AA
78
Apriem Advisors
Irvine,
California
| $1K | – | – | – |
|
|
KF
79
Krilogy Financial
St. Louis,
Missouri
| $1K | – | – | – |
|
|
VCM
80
Vivaldi Capital Management
Chicago,
Illinois
| $33 | +$41.9K | +6 | New |
|
|
KCM
81
Knoll Capital Management
Miami,
Florida
| – | -$1.55M | -233 | Closed |
|
|
82
Norges Bank
Oslo,
Norway
| – | -$356K | -53 | Closed |
|
|
TSS
83
Two Sigma Securities
New York
| – | -$23K | -3 | Closed |
|
84
HSBC Holdings
London,
United Kingdom
| – | -$13K | -2 | Closed |
|
85
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$13K | -2 | Closed |
|
TOVX Hedge Fund Activity: Q1 2017 in Review
74 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2017, worth a combined $27.4M — down 19% from $34M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TOVX positions and 7 closed out — a net gain of 8 holders — while 13 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $4.45M. The largest seller was Knoll Capital Management, exiting entirely with an estimated $1.55M sold.
- 74 institutional investors held Theriva Biologics (TOVX) as of Q1 2017, up from 70 in Q4 2016.
- Funds reported $27.4M of Theriva Biologics stock for Q1 2017, down 19% quarter-over-quarter.
- 15 funds opened new Theriva Biologics positions in Q1 2017 and 7 closed out, a net change of +8 holders.
- The largest Theriva Biologics buyer in Q1 2017 was BlackRock, an estimated $4.45M added.
- The largest Theriva Biologics seller in Q1 2017 was Knoll Capital Management, an estimated $1.55M sold.
Based on aggregated 13F filings for Q1 2017.